Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
107actual
Sites
8
Country
Mexico
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-08 | actual | When the study began enrolling |
| Primary completion | 2025-05-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Spasticity
Primary outcomes
what the primary-completion date above is the date OFAbsolute Total Dose
measured Up to 12 months
Total Dose Per Kilogram
measured Up to 12 months
Dose Per Muscle
measured Up to 12 months
Application Sites Number Per Muscle
measured Up to 12 months
Re-administration Interval
measured Up to 12 months
Needle Gauge
measured Up to 12 months
Needle Length
measured Up to 12 months
Preventive Pain Management Technique
measured Up to 12 months
Method to Locate Application Site
measured Up to 12 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed